AI Resilience Report forUrologists

Right now, AI in urology is mostly augmenting doctors rather than replacing them — meaning it helps urologists work faster and catch things they might miss, not do their jobs for them. According to the latest AUA workforce data, 37% of urologists are routinely incorporating AI into their practice, most commonly for clinical documentation, chart summaries and translation services ^[1], and AI-powered scribes now have the highest access rate at 38%. A recent Urology Times session showed the range of tools urologists actually touch: AI applications from the moment a patient enters the clinic through diagnostics, surgery, and post-visit documentation ^[2], including agentic AI systems capable of generating operative notes directly from surgical video and ambient AI that extends beyond dictation to clinical decision support.

On the diagnostic side, the FDA has cleared tools like Ibex Prostate Detect, which uses AI to analyze prostate biopsy images and generate heatmaps that flag tumors human pathologists missed ^[3] — a direct assist for the "interpret diagnostic tests" task. In the operating room, a 2026 Nature Reviews Urology review explains that AI in robotic surgery is producing assistive systems that enhance perception, anticipate risks and standardize feedback while remaining under surgeon control ^[4], which fits the very low automation scores for surgical tasks.

Adoption is picking up quickly for paperwork because commercial tools are cheap, plug into Epic, and directly attack burnout — urologists report a median 55-hour work week, with one-third working over 60 hours ^[1], so any minute saved is valuable. A workforce shortage — most U.S. counties (62%) do not have a practicing urologist ^[1] — also pushes practices to use AI to stretch capacity.

Adoption is slower for clinical decisions and surgery. Urology Times reports that a JAMA cohort study of 8,581 clinicians found AI scribe adoption had only a modest impact ^[2], showing hype outruns real productivity gains. High-stakes tasks also face big hurdles: FDA authorization, liability, and cost.

Even the ArteraAI Prostate prognostic tool required De Novo FDA authorization ^[5] before urologists could rely on it. And a European Association of Urology scoping review warns that generative AI raises concerns around accuracy, bias, privacy and accountability in patient counselling ^[6], meaning trust must be earned before AI touches diagnosis or treatment decisions.

The hopeful takeaway: surgery, empathy, judgment calls, and hands-on procedures — the parts of urology with 3% automation scores — remain deeply human. AI is shaping up to be a helpful assistant that gives future urologists more time with patients, not a replacement.